Bedrijfsoverzicht
Illumina, Inc. is a leading provider of sequencing- and array-based solutions designed for comprehensive genetic and genomic analysis across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company operates within the Healthcare sector, specifically focusing on the Diagnostics & Research industry, which positions it at the forefront of technological advancements in biological data generation. With a market capitalization of $18.49 billion and an annual revenue of $4.34 billion, the firm demonstrates significant scale supported by a workforce of 8,600 employees. These valuation and revenue metrics indicate that Illumina holds a substantial position in the global genomic market, reflecting high market confidence in its core products and services. The breadth of its geographic presence combined with its robust financial size underscores its role as a major infrastructure player for life science research and clinical diagnostics.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $4.34 billion, generating net income of $850.00 million and an EBITDA of $1.14 billion. The significant gap between revenue and net income reveals a cost structure where operating expenses, including research and development and sales costs, consume approximately 80.4% of total revenue before arriving at the bottom line. Free cash flow stands at $786.00 million, indicating strong operational efficiency and providing the financial flexibility to fund capital expenditures, acquisitions, or share buybacks without relying on external financing. Profitability is further highlighted by a gross margin of 68.2%, an operating margin of 19.7%, and a profit margin of 19.6%, which collectively suggest a high-margin business model typical of specialized technology and consumable sales. On the balance sheet, the company holds $1.63 billion in cash against $2.55 billion in debt, resulting in a debt-to-equity ratio of 93.76, which indicates a leveraged capital structure rather than a conservative one. Despite the leverage, the current ratio of 2.08 signals robust short-term liquidity, as the firm possesses more than double the current assets required to cover its short-term obligations. Management effectiveness is evidenced by a Return on Equity of 33.4% and a Return on Assets of 8.4%, showing that the company generates substantial returns relative to the shareholder equity invested.
Waarderingsbeoordeling
Valuation multiples for Illumina include a trailing P/E ratio of 22.19 and a forward P/E of 20.75. The difference between these two metrics implies that the market expects earnings to grow in the coming year, as the forward multiple is lower than the trailing multiple. The price-to-book ratio is 6.79, indicating that the stock trades at a significant premium over its book value, reflecting the intangible assets and growth potential inherent in the biotechnology sector. Alternative valuation metrics such as a price-to-sales ratio of 4.26 and an EV/EBITDA of 17.04 provide further context, suggesting the market values the company's sales generation and earnings power at levels consistent with high-growth healthcare firms. Regarding price action, the 52-week high is $155.53 and the 52-week low is $69.83, with the current trading price situated between these bounds. The beta value of 1.49 indicates that the stock exhibits higher volatility than the broader market, moving approximately 1.5 times as much as the market index during periods of fluctuation.
Growth & Income
Revenue growth is currently 5.0% year-over-year, while earnings growth is significantly higher at 86.4% year-over-year. This divergence implies that earnings are expanding at a much faster rate than revenue, likely driven by leverage effects, margin expansion, or one-time accounting adjustments that have disproportionately boosted the bottom line. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that earnings are reinvested into research, development, and business expansion rather than being distributed to shareholders. This reinvestment strategy is common for technology companies in the growth phase, prioritizing long-term market share acquisition and product innovation over immediate income generation for investors. Overall, the company presents a growth-oriented profile characterized by accelerating earnings performance and a capital allocation strategy focused on internal expansion rather than dividend distributions.